Streetbeat News

Analyst Ratings

EWBC

Wells Fargo analyst Timur Braziler has maintained an Overweight rating on East West Bancorp (NASDAQ:EWBC) and raised the price target from $95 to $97.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:30 pm

FBP

Wells Fargo analyst Timur Braziler has maintained an Equal-Weight rating on First BanCorp (NYSE:FBP) while raising the price target from $20 to $22.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:28 pm

FHB

Wells Fargo analyst Timur Braziler has maintained an Underweight rating on First Hawaiian (NASDAQ:FHB) and lowered the price target from $22 to $20.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:26 pm

WAL

Wells Fargo analyst Timur Braziler has maintained an Equal-Weight rating on Western Alliance (NYSE:WAL) while raising the price target from $85 to $92.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:24 pm

BA

Wells Fargo analyst Matthew Akers has maintained an Underweight rating on Boeing and lowered the price target from $119 to $110.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:21 pm

BAH

Wells Fargo analyst Matthew Akers has maintained an Overweight rating on Booz Allen Hamilton and raised the price target from $165 to $185.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:19 pm

CACI

Wells Fargo analyst Matthew Akers has maintained an Overweight rating on CACI International and raised the price target from $525 to $577.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:15 pm

LDOS

Wells Fargo analyst Matthew Akers has maintained an Overweight rating on Leidos Holdings (NYSE:LDOS) and raised the price target from $172 to $183.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:14 pm

TMO

Stephens initiated coverage on Thermo Fisher Scientific (NYSE:TMO), highlighting its leadership in the life science tools/services/diagnostics industry. The company is well-positioned for growth, particularly in the biopharma sector, due to its strategic mergers and acquisitions. Thermo Fisher's contract development and manufacturing organization (CDMO) is set to benefit from the demand for GLP-1 weight loss drugs and biologics production. Stephens rated the stock as Overweight with a price target of $680.

Portfolio Pulse from Vandana Singh

October 01, 2024 | 7:12 pm

APA

Wells Fargo analyst Roger Read maintains an Overweight rating on APA Corporation but lowers the price target from $49 to $47.

Portfolio Pulse from Benzinga Newsdesk

October 01, 2024 | 7:08 pm